SEC Form 4 · accession 0000905148-26-003041
Acrivon Therapeutics, Inc. · ACRV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sharon Shacham
Director
Period of report
Jun 17, 2026
Accepted (ET)
Jun 22, 2026 · 4:13 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001781174
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $1.52 | Jun 17, 2026 | A | 20,275 | A | — | Jun 16, 2036 | Common Stock | 20,275 | 20,275 | D |
Explanation of responses
- F1The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date.